123 related articles for article (PubMed ID: 2942246)
21. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
Sasagawa I; Satomi S; Umeda K; Katayama T
Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
[TBL] [Abstract][Full Text] [Related]
22. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
[TBL] [Abstract][Full Text] [Related]
23. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
24. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
Flamm J; Spona J
Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
[TBL] [Abstract][Full Text] [Related]
25. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
26. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
Lorenz I; Mechl Z
Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
[TBL] [Abstract][Full Text] [Related]
28. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
29. [Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases].
Amadori D; Ravaioli A; Barbanti F
Minerva Med; 1977 Dec; 68(59):3967-80. PubMed ID: 74811
[TBL] [Abstract][Full Text] [Related]
30. [Results of a pilot study with high-dose medroxyprogesterone acetate in the treatment of metastasizing breast carcinoma].
Castiglione M; Cavalli F
Schweiz Med Wochenschr; 1980 Jul; 110(27-28):1073-6. PubMed ID: 7423153
[TBL] [Abstract][Full Text] [Related]
31. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
[TBL] [Abstract][Full Text] [Related]
32. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
Wander HE; Nagel GA; Blossey HC
Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
[TBL] [Abstract][Full Text] [Related]
33. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
[TBL] [Abstract][Full Text] [Related]
34. [Sequential therapy with antiestrogens and progestational drugs in carcinoma of the breast in an advanced stage].
Palmeri R; Papalia E; Lazzara S; Belnome NA; Gorgone S; Calbo E; Melita P
Chir Ital; 1987 Apr; 39(2):185-92. PubMed ID: 2958166
[TBL] [Abstract][Full Text] [Related]
35. [High-dose gestagen therapy with medroxyprogesterone acetate in metastasizing breast carcinoma].
Bastert G; Michel RT
Med Welt; 1983 Mar; 34(12):378-82. PubMed ID: 6222235
[No Abstract] [Full Text] [Related]
36. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681
[TBL] [Abstract][Full Text] [Related]
37. Medroxyprogesterone acetate and lipid metabolic changes.
Teichmann AT; Wander HE; Cremer P; Wieland H; Kuhn W; Nagel GA; Seidel D
Arzneimittelforschung; 1987 May; 37(5):573-7. PubMed ID: 2956958
[TBL] [Abstract][Full Text] [Related]
38. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W
Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397
[No Abstract] [Full Text] [Related]
39. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.
Yamashita J; Hideshima T; Shirakusa T; Ogawa M
Cancer; 1996 Dec; 78(11):2346-52. PubMed ID: 8941005
[TBL] [Abstract][Full Text] [Related]
40. [High-dose gestagen therapy in breast cancer].
Beaufort F; Fereberger W
Wien Med Wochenschr; 1983 Apr; 133(7):169-73. PubMed ID: 6223450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
